A new wrist device called Neupulse has shown promising results in reducing tic frequency in people with Tourette's syndrome. In a 2023 clinical trial of 121 people in the UK, wearing the device reduced tic frequency by an average of 25%. The device, developed by the University of Nottingham and its spin-out company Neurotherapeutics Ltd, sends rhythmic electrical pulses into the median nerve, which runs through the wrist and into the hand. This stimulation has been shown to change activity in the brain regions responsible for movement control, and lower both the frequency and intensity of tics. The device has been described as 'life-changing' by users, who have reported being able to manage their tics more effectively. One user, Katie, was able to get through her wedding vows without ticking, while another user, Ollie, was able to stop his involuntary neck movement after using the device. The device has also been used by people with functional neurological disorder (FND), a condition that affects how the brain sends and receives signals. The device's developer, Professor Stephen Jackson, has described the response from users as 'a dream come true'. The device is set to go on sale after securing £1 million in additional funding. The condition of Tourette's syndrome affects over 300,000 people in the UK, and there is currently no cure. The device offers new hope for those affected by the condition, and its development is a significant step forward in the treatment of Tourette's syndrome.
This Tourette’s wrist device cut tics by a quarter in a UK trial
Prepared with AI assistance; not independently fact-checked. Original source: The Optimist Daily